Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.

Essock-Burns E, Lupo JM, Cha S, Polley MY, Butowski NA, Chang SM, Nelson SJ.

Neuro Oncol. 2011 Jan;13(1):119-31. doi: 10.1093/neuonc/noq143. Epub 2010 Oct 29.

2.

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.

Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE.

J Clin Oncol. 2009 Aug 10;27(23):3861-7. doi: 10.1200/JCO.2008.20.7944. Epub 2009 Jun 8.

3.

Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.

Donato V, Papaleo A, Castrichino A, Banelli E, Giangaspero F, Salvati M, Delfini R.

Tumori. 2007 May-Jun;93(3):248-56.

4.

Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.

Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, Lanzetta G, Scarpino S, Arcella A, Enrici RM.

Radiother Oncol. 2010 Dec;97(3):377-81. doi: 10.1016/j.radonc.2010.08.020. Epub 2010 Sep 18.

PMID:
20855119
5.

Population-based study of pseudoprogression after chemoradiotherapy in GBM.

Roldán GB, Scott JN, McIntyre JB, Dharmawardene M, de Robles PA, Magliocco AM, Yan ES, Parney IF, Forsyth PA, Cairncross JG, Hamilton MG, Easaw JC.

Can J Neurol Sci. 2009 Sep;36(5):617-22.

PMID:
19831132
6.

Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme.

Roldán Urgoiti GB, Singh AD, Easaw JC.

J Neurooncol. 2012 May;108(1):173-7. doi: 10.1007/s11060-012-0826-3. Epub 2012 Mar 2.

PMID:
22382781
7.

Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis.

Erpolat OP, Akmansu M, Goksel F, Bora H, Yaman E, Büyükberber S.

Tumori. 2009 Mar-Apr;95(2):191-7.

8.

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.

Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M.

J Clin Oncol. 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163.

9.

Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.

Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, Innocenzi G, Gagliardi FM, Salvati M, Minniti G, Frati A, Frati L, Vecchione A.

Anticancer Res. 2003 Nov-Dec;23(6D):5159-64.

PMID:
14981983
10.

Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.

Birol Sarica F, Tufan K, Cekinmez M, Sen O, Cem Onal H, Mertsoylu H, Topkan E, Pehlivan B, Erdogan B, Nur Altinors M.

J Neurosurg Sci. 2010 Mar;54(1):7-19.

PMID:
20436394
11.

The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.

Sher DJ, Henson JW, Avutu B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG 2nd, Loeffler JS, Chakravarti A.

J Neurooncol. 2008 May;88(1):43-50. doi: 10.1007/s11060-008-9530-8. Epub 2008 Jan 30.

12.

Short-term radiotherapy followed by adjuvant chemotherapy in poor-prognosis patients with glioblastoma.

Muni R, Minniti G, Lanzetta G, Caporello P, Frati A, Enrici MM, Marchetti P, Enrici RM.

Tumori. 2010 Jan-Feb;96(1):60-4.

13.

Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.

Sanghera P, Perry J, Sahgal A, Symons S, Aviv R, Morrison M, Lam K, Davey P, Tsao MN.

Can J Neurol Sci. 2010 Jan;37(1):36-42.

PMID:
20169771
14.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.

N Engl J Med. 2005 Mar 10;352(10):987-96.

15.

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE 2nd, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, Bigner DD.

J Clin Oncol. 2010 Nov 1;28(31):4722-9. doi: 10.1200/JCO.2010.28.6963. Epub 2010 Oct 4.

16.

Prognostic significance of concomitant radiotherapy in newly diagnosed glioblastoma multiforme: a multivariate analysis of 116 patients.

Okumus NO, Gursel B, Meydan D, Ozdemir O, Odabas E, Gonullu G.

Ann Saudi Med. 2012 May-Jun;32(3):250-5. doi: 10.5144/0256-4947.2012.250.

PMID:
22588435
17.

Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.

Yun TJ, Park CK, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Kim IH, Choi SH.

Radiology. 2015 Mar;274(3):830-40. doi: 10.1148/radiol.14132632. Epub 2014 Oct 21.

PMID:
25333475
18.

[Temozolomide in patients with a glioblastoma multiforme: new developments].

Bromberg JE, Postma TJ.

Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1376-8. Dutch.

PMID:
15997689
19.

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.

Lou E, Peters KB, Sumrall AL, Desjardins A, Reardon DA, Lipp ES, Herndon JE 2nd, Coan A, Bailey L, Turner S, Friedman HS, Vredenburgh JJ.

Cancer Med. 2013 Apr;2(2):185-95. doi: 10.1002/cam4.58. Epub 2013 Jan 24.

20.

First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.

Bock HC, Puchner MJ, Lohmann F, Schütze M, Koll S, Ketter R, Buchalla R, Rainov N, Kantelhardt SR, Rohde V, Giese A.

Neurosurg Rev. 2010 Oct;33(4):441-9. doi: 10.1007/s10143-010-0280-7. Epub 2010 Aug 13.

Items per page

Supplemental Content

Write to the Help Desk